^
    Back
    Association details:
    Biomarker:BRCA1 mutation + TMB-H
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    JCO Precis Oncol
    Title:

    Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review

    Published date:
    01/27/2022
    Excerpt:
    Here, we present a case of metastatic pancreatic adenocarcinoma harboring a germline BRCA1 mutation and a high tumor mutation burden (TMB), demonstrating an excellent response to initial platinum-based chemotherapy, followed by a complete radiologic response to maintenance immunotherapy and poly (ADP-ribose) polymerase (PARP) inhibition....In conclusion, this case report describes a profound clinical response to sequential platinum-based chemotherapy, pembrolizumab, and olaparib in a patient with advanced PC harboring a germline BRCA1 mutation and high TMB.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1200/PO.21.00437